Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
-
* Corresponding author: Shalini L Kulasingam kulas002@mc.duke.edu
Cost Effectiveness and Resource Allocation 2008, 6:4 doi:10.1186/1478-7547-6-4
Accesses
- Last 30 days: 96 accesses
- Last 365 days: 1601 accesses
- All time: 8313 accesses